Close Menu

NEW YORK – Liquid biopsy firm Biocept on Monday priced a previously announced underwritten public offering of 24,600,000 shares of its common stock paired with warrants to purchase up to the same number of shares. 

Gross proceeds from the offering are expected to be about $10 million, which it will use to support ongoing operations and expansion of its business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.